Publication:
Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: A randomized controlled trial

dc.contributor.authorWeerachai Srivanichakornen_US
dc.contributor.authorApiradee Sriwijitkamolen_US
dc.contributor.authorAroon Kongchooen_US
dc.contributor.authorSutin Sriussadapornen_US
dc.contributor.authorNattachet Plengvidhyaen_US
dc.contributor.authorR. Aweewan Lertwattanaraken_US
dc.contributor.authorSathit Vannasaengen_US
dc.contributor.authorNuntakorn Thongtangen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-23T10:48:59Z
dc.date.available2018-11-23T10:48:59Z
dc.date.issued2015-03-02en_US
dc.description.abstract© 2015 Srivanichakorn et al. Background: The benefit of sulfonylureas (SUs) to patients with type 2 diabetes mellitus receiving long-term insulin treatment is unclear. This study evaluated glycemic control and beta-cell function after SU withdrawal in these patients. Methods: In this 8-week randomized controlled study, patients with type 2 diabetes who had been treated with insulin for at least 3 years plus moderate to high doses of SUs were randomly assigned to withdrawal (n=16) or continuation (n=16) of SUs. Clinical characteristics, glycemic control, hypoglycemic events, and insulin secretion, including homeostasis model assessment of beta-cell function (HOMA-B) score, C-peptide concentration, and Matsuda index, were evaluated at baseline and after 2 and 8 weeks. Results: Thirty patients (16 in the SU withdrawal group and 14 in the SU continuation group) completed the study. Median duration of diabetes was 17 (range 5–40) years. Baseline clinical characteristics, glycemic control, and HOMA-B were similar in the two groups, but the mean fasting C-peptide concentration was higher in the SU withdrawal group. After 8 weeks, the SU withdrawal group showed a significant increase in mean glycosylated hemoglobin levels from 7.8%±0.5% (62±5 mmol/mol) to 8.6%±1.2% (71±13 mmol/mol; P=0.002), whereas the SU continuation group showed a slight but not significant increase from 7.7%±0.5% (61±5 mmol/mol) to 7.9%±1.2% (63±13 mmol/mol; P=0.37). Insulin secretion, as measured by C-peptide and HOMA-B, decreased by 18% and 36%, respectively, in the SU withdrawal group. Hypoglycemic events were significantly more frequent in the SU continuation group whereas body weight did not change significantly in either group. Conclusion: Withdrawal of SU from patients with type 2 diabetes receiving long-term combination treatment with SU and insulin resulted in deterioration of glycemic control and insulin secretion.en_US
dc.identifier.citationDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy. Vol.8, (2015), 137-145en_US
dc.identifier.doi10.2147/DMSO.S78008en_US
dc.identifier.issn11787007en_US
dc.identifier.other2-s2.0-84924184234en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/36497
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84924184234&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleWithdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: A randomized controlled trialen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84924184234&origin=inwarden_US

Files

Collections